BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8468272)

  • 1. Solid second cancers following Hodgkin's disease.
    Tucker MA
    Hematol Oncol Clin North Am; 1993 Apr; 7(2):389-400. PubMed ID: 8468272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Second malignancies in patients treated for Hodgkin's disease].
    Keresztes K; Miltényi Z; András C; Illés A
    Magy Onkol; 2002; 46(3):247-51. PubMed ID: 12368920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second malignancies following treatment for Hodgkin's disease: a Greek experience.
    Economopoulos T; Stathakis N; Alexopoulos C; Pavlidis N; Constantinidou M; Briassoulis E; Papageorgiou E; Dervenoulas J; Pappa V; Vaslamatzis M
    Haematologica; 1994; 79(3):273-6. PubMed ID: 7926979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Secondary tumors in Hodgkin's disease patients].
    Kovryzhkina TA; Il'in NV; Verbovetskaia VI; Shenderova IA; Smirnova EV
    Vopr Onkol; 2001; 47(5):626-30. PubMed ID: 11785109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
    Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
    Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
    J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects.
    Donaldson SS; Hancock SL; Hoppe RT
    Cancer J Sci Am; 1999; 5(6):325-33. PubMed ID: 10606471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second cancers after Hodgkin's disease in childhood.
    Donaldson SS; Hancock SL
    N Engl J Med; 1996 Mar; 334(12):792-4. PubMed ID: 8592556
    [No Abstract]   [Full Text] [Related]  

  • 11. [New cancer disease after treatment of Hodgkin's disease].
    Abrahamsen JF; Andersen A; Hannisdal E; Nome O; Kvaløy SO; Høst H; Abrahamsen AF
    Tidsskr Nor Laegeforen; 1993 Sep; 113(23):2903-5. PubMed ID: 8236191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Late treatment related complications of Hodgkin's disease].
    Henry-Amar M; Gisselbrecht C
    Rev Prat; 1998 May; 48(10):1092-7. PubMed ID: 9781154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second cancers following pediatric Hodgkin's disease.
    Wolden SL; Lamborn KR; Cleary SF; Tate DJ; Donaldson SS
    J Clin Oncol; 1998 Feb; 16(2):536-44. PubMed ID: 9469338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period)].
    Jakó J; Szerafin L; Nagy P
    Orv Hetil; 2005 Mar; 146(10):461-9. PubMed ID: 15835344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis.
    Hemminki K; Lenner P; Sundquist J; Bermejo JL
    J Clin Oncol; 2008 Apr; 26(11):1850-7. PubMed ID: 18347006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second cancers after treatment of Hodgkin's disease: experience at the International Database on Hodgkin's disease (IDHD)].
    Henry-Amar M
    Bull Cancer; 1992; 79(4):389-91. PubMed ID: 1421702
    [No Abstract]   [Full Text] [Related]  

  • 18. [Solid tumours after treatment for Hodgkin's disease (author's transl)].
    Unger PF; Auclerc G; Weil M; Jacquillat C
    Nouv Presse Med; 1981 Apr; 10(18):1463-7. PubMed ID: 7255119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.
    Swerdlow AJ; Douglas AJ; Hudson GV; Hudson BV; Bennett MH; MacLennan KA
    BMJ; 1992 May; 304(6835):1137-43. PubMed ID: 1392790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.